Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

By sjmartinez • March 28, 2023

Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023 Mar 18;15:265-275. doi: 10.2147/CMAR.S341468. PMID: 36969544; PMCID: PMC10032141.

Tags: gastric cancer, gastroesophageal junction cancer, Hematology/Oncology, immune checkpoint inhibition, immunotherapy, PD-L1, Publications

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]